Director, Pulmonary Vascular Disease Program
Pulmonology
Dr. Aaron B. Waxman, MD
|
|
Give Review
Aaron B. Waxman, MD works in the field of Pulmonology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine Aaron Waxman is a published doctor and has 36 publications published. The lastest was: 'Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge.' He is registered with Medicare.
Publications
- Anticoagulation in patients with Pulmonary arterial hypertension: An update on current knowledge.
- Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with Pulmonary arterial hypertension.
- Right Heart failure: toward a common language.
- Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation.
- Towards Widespread Noninvasive Assessment of Pulmonary Vascular Resistance in Clinical Practice.
- Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials).
- A Simple Echocardiographic Method to Estimate Pulmonary Vascular Resistance.
- Transcatheter Potts shunt creation in patients with severe Pulmonary arterial hypertension: initial clinical experience.
- The invasive cardioPulmonary exercise test.
- Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
- Plasma aldosterone levels are elevated in patients with Pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.
- Oral prostacyclin therapy for Pulmonary arterial hypertension: another step forward.
- Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of Pulmonary arterial hypertension.
- Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?
- Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in Pulmonary arterial hypertension.
- Circulating endothelial and endothelial progenitor cells in patients with severe sepsis.
- The inflammasome mediates hyperoxia-induced alveolar cell permeability.
- IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins.
- IL-6 cytoprotection in hyperoxic acute Lung injury occurs via PI3K/Akt-mediated Bax phosphorylation.
- IL-6 cytoprotection in hyperoxic acute Lung injury occurs via suppressor of cytokine signaling-1-induced apoptosis signal-regulating kinase-1 degradation.
- Interleukin-6 overexpression induces Pulmonary hypertension.
- Exercise-induced Pulmonary arterial hypertension.
- Cicletanine for the treatment of Pulmonary arterial hypertension.
- Multicenter implementation of a consensus developed, evidence-based, spontaneous Breathing trial protocol.
- Plasma gelsolin depletion and circulating actin in sepsis: a pilot study.
- Pulmonary arterial hypertension: evaluation and management.
- Plasma gelsolin is a marker and therapeutic agent in animal sepsis.
- Conversion to bosentan from prostacyclin infusion therapy in Pulmonary arterial hypertension: a pilot study.
- DNA damage induced by hyperoxia: quantitation and correlation with Lung injury.
- Modulation of IGF-binding protein-2 and -3 in hyperoxic injury in developing rat Lung.
- Bcl-2-related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute Lung injury.
- Interleukin-11 and interleukin-6 protect cultured human endothelial cells from H2O2-induced cell death.
- Pulmonary hypertension: work in progress.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2003. A 73-year-old woman with Pneumonia and progressive respiratory ...
- Phosphodiesterase-5 Inhibitors.
Schools
Yale University School Of Medicine
Yale New Haven Hospital
Procedures Preformed
- Bronchoscopy
- Central Line Insertion (for Chemotherapy)
- Right Heart Catheterization (Swan-Ganz)
- Ventilation Management
Conditions Treated
- Acidosis
- Asthma
- Atelectasis
- Breathing Disorders
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Education
-
Yale-New Haven Hospital -
Yale University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Brigham and Women's Faulkner Hospital
Drug Facts
| NPI NUMBER | 1669461810 | |
| NPPES Provider LastName | WAXMAN | |
| NPPES Provider FirstName | AARON | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 1045.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669461810 |
| Last Name Of The Provider | WAXMAN |
| First Name Of The Provider | AARON |
| View All |
Similar Doctors
|
|
Dr. Jeanine P. Wiener-Kronish, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine A. Dudley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David C. Christiani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ja J. Martyn, MB |
|
|
Michael Nurok, MB CHB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharma E. Joseph, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles C. Hardin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelan Tantisira, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joshua A. Englert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Lacy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter J. O Donnell, MD |
|
|
Dr. Ednan K. Bajwa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karin A. Sloan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heidi B. Kummer, MD |
|
|
Dr. Ronald H. Goldstein, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|